Prognostic and immunological profiling of SEC61G in cervical squamous cell carcinoma and adenocarcinoma

Cervical squamous cell carcinoma and adenocarcinoma are major challenges to women's health worldwide, with incidence and mortality rates ranking first among female reproductive tract malignancies in China. The correlation between the SEC61G gene and cervical squamous cell carcinoma and adenocarcinoma remains unclear. In this study, we aimed to demonstrate the prognostic value and potential biological function of SEC61G in these cancers.

This study obtained pan-cancer and cervical squamous cell carcinoma and adenocarcinoma data from UCSC XENA. Cox regression analysis and Kaplan-Meier survival analysis were used to evaluate the prognostic value of SEC61G in pan-cancer and cervical cancers. TIMER and CIBERSORT were used to assess the relationship between SEC61G expression and immune cell populations.

Elevated expression of SEC61G was observed in various malignancies. Kaplan-Meier survival analysis demonstrated a significant association between SEC61G expression and overall survival (OS) in multiple cancers, including cervical squamous cell carcinoma and adenocarcinoma. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that SEC61G has substantial diagnostic utility for cervical cancers as well as other malignancies. Additionally, correlation analyses revealed a significant relationship between SEC61G expression and immune cell populations.

This study provides the first comprehensive analysis of the role of SEC61G in pan-cancer and cervical squamous cell carcinoma and adenocarcinoma. Our findings suggest that SEC61G can serve as a diagnostic biomarker and prognostic indicator for cervical cancers.